CNS Pharmaceuticals (CNSP) Expected to Announce Earnings on Wednesday

CNS Pharmaceuticals (NASDAQ:CNSP) is projected to issue its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($5.09) per share for the quarter.

CNS Pharmaceuticals Price Performance

CNSP stock traded up $0.05 during trading hours on Friday, reaching $3.24. The stock had a trading volume of 10,112 shares, compared to its average volume of 52,570. The stock has a 50-day simple moving average of $5.62 and a 200 day simple moving average of $6.83. CNS Pharmaceuticals has a fifty-two week low of $3.09 and a fifty-two week high of $55.20. The stock has a market capitalization of $2.01 million, a PE ratio of -0.10 and a beta of 2.70.

Hedge Funds Weigh In On CNS Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Boothbay Fund Management LLC acquired a new stake in CNS Pharmaceuticals during the 4th quarter worth approximately $71,000. Ikarian Capital LLC bought a new position in CNS Pharmaceuticals during the 4th quarter worth $241,000. Finally, Armistice Capital LLC acquired a new stake in shares of CNS Pharmaceuticals during the second quarter worth $335,000. Institutional investors own 14.02% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, CNS Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $20.00.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.